Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma

被引：4

作者：

Ambady, Prakash ^{[1
]}

Fu, Rongwei ^{[2
]}

Szidonya, Laszlo ^{[1
]}

Peereboom, David M. ^{[3
]}

Doolittle, Nancy D. ^{[1
]}

Neuwelt, Edward A. ^{[1
,4
,5
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Sam Jackson Pk Rd,L603, Portland, OR 97239 USA

[2] Oregon Hlth & Sci Univ, Sch Publ Hlth, Dept Clin Epidemiol & Med Informat, Portland, OR 97201 USA

[3] Cleveland Clin, Burkhardt Brain Tumor Ctr, Cleveland, OH 44106 USA

[4] Oregon Hlth & Sci Univ, Dept Neurosurg, Portland, OR 97201 USA

[5] Portland VA Med Ctr, Portland, OR 97239 USA

来源：

JOURNAL OF NEURO-ONCOLOGY | 2020年 / 147卷 / 01期

关键词：

Primary CNS lymphoma; Maintenance therapy; Rituximab; High-dose methotrexate; PRIMARY CNS LYMPHOMA; BLOOD-BRAIN-BARRIER; CHEMOTHERAPY; METHOTREXATE; DISRUPTION; SURVIVAL; THERAPY;

D O I：

10.1007/s11060-020-03411-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose The role of maintenance immunotherapy with anti-CD20 monoclonal antibody rituximab in primary central nervous system lymphoma (PCNSL) is unclear. We retrospectively reviewed the medical records of all immunocompetent adults with newly diagnosed PCNSL treated at our institution between1996 and 2017. Methods We identified 66 patients who attained complete response (CR) after completion of first-line regimen; 20 received maintenance therapy (maintenance therapy group) and 46 were observed with serial MRI scans without maintenance therapy (no-maintenance therapy group). Results Compared to the surveillance group, there was a significant increase in duration of survival (HR 0.27, 95% CI 0.08-0.98, P = 0.046) in the maintenance therapy group while the reduction in the risk of progression was not significant (HR: 0.61, 95% CI 0.26-1.43, P = 0.259). Conclusion We are evaluating the effectiveness of maintenance immunotherapy in PCNSL in a prospective multicenter randomized clinical trial.

引用

页码：171 / 176

页数：6

共 23 条

[1] Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma [J].

Abrey, LE ;

Batchelor, TT ;

Ferreri, AJM ;

Gospodarowicz, M ;

Pulczynski, EJ ;

Zucca, E ;

Smith, JR ;

Korfel, A ;

Soussain, C ;

DeAngelis, LM ;

Neuwelt, EA ;

O'Neill, BP ;

Thiel, E ;

Shenkier, T ;

Graus, F ;

van den Bent, M ;

Seymour, JF ;

Poortmans, P ;

Armitage, JO ;

Cavalli, F .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5034-5043

[2] Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease [J].

Ambady, Prakash ;

Fu, Rongwei ;

Netto, Joao Prola ;

Kersch, Cymon ;

Firkins, Jenny ;

Doolittle, Nancy D. ;

Neuwelt, Edward A. .

FLUIDS AND BARRIERS OF THE CNS, 2017, 14

[3]

Ambady Prakash, 2015, CNS Oncol, V4, P393, DOI 10.2217/cns.15.34

[4] Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience [J].

Angelov, Lilyana ;

Doolittle, Nancy D. ;

Kraemer, Dale F. ;

Siegal, Tali ;

Barnett, Gene H. ;

Peereboom, David M. ;

Stevens, Glen ;

McGregor, John ;

Jahnke, Kristoph ;

Lacy, Cynthia A. ;

Hedrick, Nancy A. ;

Shalom, Edna ;

Ference, Sandra ;

Bell, Susan ;

Sorenson, Lisa ;

Tyson, Rose Marie ;

Haluska, Marianne ;

Neuwelt, Edward A. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) :3503-3509

[5] Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study [J].

Bromberg, Jacoline E. C. ;

Issa, Samar ;

Bakunina, Katerina ;

Minnema, Monique C. ;

Seute, Tatjana ;

Durian, Marc ;

Cull, Gavin ;

Schouten, Harry C. ;

Stevens, Wendy B. C. ;

Zijlstra, Josee M. ;

Baars, Joke W. ;

Nijland, Marcel ;

Mason, Kylie D. ;

Beeker, Aart ;

van den Bent, Martini ;

Beijert, Max ;

Gonzales, Michael ;

de Jong, Daphne ;

Doorduijn, Jeanette K. .

LANCET ONCOLOGY, 2019, 20 (02) :216-228

[6]

Doolittle ND, 2010, BLOOD, V116, P1151

[7]

Doolittle ND, 2000, CANCER, V88, P637, DOI 10.1002/(SICI)1097-0142(20000201)88:3<637::AID-CNCR22>3.0.CO

[8]

2-Y

[9] Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial [J].

Ferreri, Andres J. M. ;

Cwynarski, Kate ;

Pulczynski, Elko ;

Ponzoni, Mourilio ;

Deckert, Martina ;

Politi, Letterio S. ;

Torri, Valter ;

Fox, Christopher P. ;

La Rosee, Paul ;

Schorb, Elisabeth ;

Ambrosetti, Achille ;

Roth, Alexander ;

Hemmoway, Claire ;

Ferrari, Angela ;

Linton, Kim M. ;

Ruda, Roberta ;

Binder, Mascha ;

Pukrop, Tobias ;

Balzarotti, Monica ;

Fabbri, Alberto ;

Johnson, Peter ;

Gorlov, Jette Sonderskov ;

Hess, Georg ;

Panse, Jens ;

Pisani, Francesco ;

Tucci, Alessandra ;

Stilgenbauer, Stephan ;

Hertenstein, Bernd ;

Keller, Ulrich ;

Krause, Stefan W. ;

Levis, Alessandro ;

Schmoll, Hans J. ;

Covalli, Franco ;

Finke, Jurgen ;

Reni, Michele ;

Zucca, Emanuele ;

Illerhaus, Gerald .

LANCET HAEMATOLOGY, 2016, 3 (05) :E217-E227

[10] Primary CNS Lymphoma [J].

Grommes, Christian ;

DeAngelis, Lisa M. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (21) :2410-+

← 1 2 3 →